Promoted Content
Promoted Content

Find Pharmacology/Toxicology Clinical Drug Pipeline Developments & Deals

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Glucarpidase

            Therapeutic Area: Pharmacology/Toxicology Product Name: Voraxaze

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Serb

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition March 02, 2021

            Details:

            BTG Specialty Pharmaceuticals has a portfolio of market-leading emergency care products, including CroFab®, Voraxaze®, and DigiFab®.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Human iPSC-derived cardiac tissues

            Therapeutic Area: Pharmacology/Toxicology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: NIH

            Deal Size: $4.6 million Upfront Cash: Undisclosed

            Deal Type: Funding March 03, 2020

            Details:

            The SBIR funding will be used to develop NanoSurface’s innovative platform for modeling and assessing human cardiac function on-a-chip.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ricin toxin

            Therapeutic Area: Pharmacology/Toxicology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 13, 2020

            Details:

            Soligenix will be eligible to submit a biologics license application (BLA) for RiVax® on a rolling basis, permitting the FDA to review sections of the BLA prior to receiving the complete submission.